Investors wondering why MoonLake Immunotherapeutics AG’s press release covering the Phase II findings on sonelokimab in psoriatic arthritis omitted the figures for the placebo group got their answer on a call today. The placebo response of 20% on the trial’s primary endpoint sorely hurt the IL-17 inhibitor’s apparent efficacy.
Placebo Response Hurts MoonLake In Psoriatic Arthritis
Sonelokimab follows a mid-stage slam-dunk in hidradenitis suppurativa with a rather more equivocal result in a different immune condition in the ARGO study.
More from Clinical Trials
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.